H.C. Wainwright raised the firm’s price target on Prothena (PRTA) to $30 from $20 and keeps a Buy rating on the shares. The firm believes the market is overlooking the company’s two partnered Phase 3 programs and a partnered Phase 2 asset with blockbuster potential.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: